This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
SOURCE: Mission Investor Relations
BioClinica enters collaborative agreement to leverage Mirada’s advanced image analysis capabilities
Atlanta, Georgia (PRWEB) March 31, 2012
MissionIR would like to highlight BioClinica, Inc., a publicly traded company and leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, Microsoft Office-Smart clinical trial management, and clinical supply chain forecasting and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia.
In the company’s news Friday,
BioClinica announced a collaborative agreement with Mirada Medical, a leading provider of medical image analysis software, to integrate Miranda’s XD3 software solution into BioClinica’s existing imaging core lab technology. This partnership will allow BioClinica to further augment its PET capabilities and expertise for molecular imaging trials.
Mirada Medical’s XD3 software delivers specialized tools along with efficient workflows used for the quantification and tracking of findings for major modalities including PET, CT, MR, and MR/PET. BioClinica’s detailed evaluation of available molecular imaging solutions led to the selection of Mirada. Mirada offers not only cutting edge image analysis, but also the ability to interface with CT and MRI as well as PET images. The application of these capabilities into BioClinica’s technology will expand and improve on image registration and fusion capabilities in studies where multiple modalities are utilized.
BioClinica opted to enter into of a tactical partnership with Mirada, rather than simply utilizing their software, with the goal of fostering innovation while molecular imaging technology continues to progress. The integration of Mirada’s XD3 software into BioClinica’s processes and workflows will greatly augment the already substantial capabilities of BioClinica’s technologies such as BioPACS and BioREAD. The combination of these technologies will result in high performing imaging workflow and processing programs capable of helping trial sponsors take advantage of the superior imaging results made available through PET scans and multi-modal technology.
This partnership will allow BioClinica’s PET image processing capabilities to support the following features:
“Adding Mirada technology to our oncology trial process takes BioClinica’s already robust imaging core lab services to a new level,” said Dr. Andy Dzik-Jurasz, BioClinica’s Senior Medical Director of Medical Affairs. “By adding XD3 to our workflow, BioClinica will offer the most sophisticated level of clinical analysis available for oncology PET scan image processing.”
“Mirada is delighted to partner with an innovative industry leader like BioClinica,” said Timor Kadir, Chief Science and Technology Officer at Mirada Medical. “We are excited to see BioClinica’s innovative utilization of XD3’s superior quantification and world class image fusion to achieve more accurate and reproducible results for their trial sponsors.”
As a result of this agreement, Mirada Medical will be presenting at BioClinica’s User Conference in October, a two day event featuring valuable presentations, case studies, and discussions aimed to help BioClinica imaging core lab customers and eClinical solutions users uncover methods producing faster, more efficient clinical trials.
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
To sign up for The MissionIR Report, please visit http://MissionIR.com
To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR
To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR
Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/3/prweb9355011.htm